SOURCE: Applied DNA Sciences

Applied DNA Sciences

August 03, 2009 08:30 ET

Applied DNA Sciences Selected for Multi-Year Contract

Spearheads Green DNA Anti-Counterfeit Program for the UK and EU

STONY BROOK, NY--(Marketwire - August 3, 2009) - Applied DNA Sciences, Inc. (OTCBB: APDN) announced that its SigNature® DNA Anti-Counterfeit technology has been selected as the sole security platform in a program funded by the European Regional Development Fund (a fund allocated by the European Union) and Yorkshire Forward. SigNature DNA applications will include the protection against counterfeiting and diversion of UK manufactured textiles from "fiber to fabric." The program will protect products from other industries as well.

APDN is one of four innovative platform technologies chosen to help accelerate the Yorkshire and Humber region's expertise in areas of growing market demand and economic importance. The other three technologies are not related to security.

"The SigNature DNA Anti-Counterfeit program was selected because it offers immediate and significant competitive advantage to the Yorkshire's high quality textile manufacturers. The public funding contribution to the Program is significant, equating to over £1 million for each of the activity areas including the APDN Anti Counterfeiting activity. This contribution is designed to generate significant additional investment from the private sector which should generate at least £2 million in each activity area over the lifetime of the Program," stated Bill Macbeth, Managing Director, Textile Centre of Excellence.

Based on the successful completion of its Trial UK Textile contract that was completed in December 2008, this extends APDN's current collaborations with Yorkshire and the Humber-based companies as part of a three-year, £5.95 million (USD$9 million) contract funded by the European Regional Development Fund and Yorkshire Forward with the Textile Centre of Excellence and Leeds University's Centre for Technical Textiles. In addition, capital equipment allocations for a DNA Authentication facility located in Huddersfield are expected to be about £250,000 (USD$400,000). APDN will rent the entire facility from the Textile Centre of Excellence. Duplicating the contract process followed in the successful Trial Contract, the formal service contract between APDN and the Textile Centre is expected to be executed by September.

The DNA Anti-Counterfeit program will support pilot studies and commercial scale-up of APDN's SigNature DNA taggants. It is anticipated that the multi-year program will fund approximately 20 projects per annum. In the first year, more than 25 commercial partners have already been identified. APDN expects the financial implications to be multifaceted. The company has already begun coordinating supply arrangements with several collaborators in Yorkshire, including Addmaster and Nilorn UK.

"Yorkshire Forward is very pleased to invest in new platform technologies that will foster growth and, ultimately, reap positive economic benefits to the Yorkshire business community, and the UK and European public at large. SigNature DNA is a true platform technology that has exciting and practical applications that extend to multiple industry sectors," added Jim Farmery, Yorkshire Forward.

In April 2009, APDN established an initial DNA testing capacity at the Textile Centre of Excellence by APDN's subsidiary, Applied DNA Sciences Europe Ltd. The facility is expanding the customer base for APDN's two DNA authentication programs, SigNature DNA and BioMaterial GenoTyping™. SigNature DNA is a botanically derived marker employed to identify originals. Recently, the facility was used to complete forensic analyses on recovered evidence for multiple UK Police groups that will be used to convict criminals who steal cash-in-transit boxes, and to repatriate recovered SigNature DNA-marked money to its original owners.

APDN's CEO, Dr. James Hayward, added: "We are immensely proud to be a significant part of this regional development contract that will involve a wide range of potential projects based on our SigNature DNA Anti-Counterfeit Program. Our European subsidiary, centered in the UK, will pursue further business development with OEMs and security integrators, as well as governments, corporations and consumers throughout the region. The benefit of the funding is to lower any barrier to entry for our regional customers, by also providing partial funding to the customer for expenses during pre-commercial pilot work. We look forward to the opportunity to successful market engagement and accelerated routes to revenue."

About APDN

APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping™ by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to www.adnas.com where APDN routinely posts all press releases.

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 16, 2008 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Contact Information

  • INVESTOR CONTACT:
    Debbie Bailey
    631-444-8090
    fax: 631-444-8848

    MEDIA CONTACT:
    Janice Meraglia
    631-444-6293
    fax: 631-444-8848

    FCMN Contact: Email Contact

    Web site: http://www.adnas.com